Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb;31(2):265-273.
doi: 10.1007/s00590-020-02765-5. Epub 2020 Aug 17.

Allogeneic umbilical cord-derived mesenchymal stem cells for treating critical-sized bone defects: a translational study

Ismail Hadisoebroto Dilogo  1   2   3 , Dina Rahmatika  4 , Jeanne Adiwinata Pawitan  4   5   6 , Isabella Kurnia Liem  4   6   7 , Tri Kurniawati  4   6 , Tera Kispa  4 , Fajar Mujadid  4
Affiliations

Allogeneic umbilical cord-derived mesenchymal stem cells for treating critical-sized bone defects: a translational study

Ismail Hadisoebroto Dilogo et al. Eur J Orthop Surg Traumatol. 2021 Feb.

Abstract

Introduction: The current 'gold-standard' treatment of critical-sized bone defects (CSBDs) is autografts; however, they have drawbacks including lack of massive bone source donor site morbidity, incomplete remodeling, and the risk of infection. One potential treatment for treating CSBDs is bone marrow-derived mesenchymal stem cells (BM-MSCs). Previously, there were no studies regarding the use of human umbilical cord-mesenchymal stem cells (hUC-MSCs) for treating BDs. We aim to investigate the use of allogeneic hUC-MSCs for treating CSBDs.

Method: We included subjects who were diagnosed with non-union fracture with CSBDs who agreed to undergo hUC-MSCs implantation. All patients were given allogeneic hUC-MSCs. All MSCs were obtained and cultured using the multiple-harvest explant method. Subjects were evaluated functionally using the Lower Extremity Functional Scale (LEFS) and radiologically by volume defect reduction.

Result: A total of seven (3 male, 4 female) subjects were recruited for this study. The subjects age ranged from 14 to 62 years. All seven subjects had increased LEFS during the end of the follow-up period, indicating improved functional ability. The follow-up period ranged from 12 to 36 months. One subject had wound dehiscence and infection, and two subjects developed partial union.

Conclusion: Umbilical cord mesenchymal stem cells are a potential new treatment for CSBDs. Additional studies with larger samples and control groups are required to further investigate the safety and efficacy of umbilical cord-derived mesenchymal stem cells for treating CSBDs.

Keywords: Critical-sized bone defect; Mesenchymal stem cells; Umbilical cord.

PubMed Disclaimer

References

    1. Liu X, Liao X, Luo E, Chen W, Bao C, Xu HHK (2014) Mesenchymal stem cells systemically injected into femoral marrow of dogs home to mandibular defects to enhance new bone formation. Tissue Eng Part A 20(3–4):883–892 - PubMed - PMC
    1. Klontzas ME, Kenanidis EI, Heliotis M, Tsiridis E, Mantalaris A (2015) Bone and cartilage regeneration with the use of umbilical cord mesenchymal stem cells. Expert Opin Biol Ther 15(11):1541–1552 - DOI
    1. Perry CR (1999) Bone repair techniques, bone graft, and bone graft substitutes. Clin Orthop Relat Res 360:71–86 - DOI
    1. Liu G, Zhao L, Zhang W, Cui L, Liu W, Cao Y (2008) Repair of goat tibial defects with bone marrow stromal cells and beta-tricalcium phosphate. J Mater Sci Mater Med 19(6):2367–2376 - DOI
    1. Micev AJ, Kalainov DM, Soneru AP (2015) Masquelet technique for treatment of segmental bone loss in the upper extremity. J Hand Surg Am 40(3):593–598 - DOI

LinkOut - more resources